Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2025)

Lineage Cell Therapeutics (LCTX) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments changed N/A year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 11011.11%, while the annual FY2025 figure was $2.0 million, 11011.11% up from the prior year.
  • Change in Acquisitions & Divestments reached $2.0 million in Q4 2025 per LCTX's latest filing, up from -$2.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $24.3 million in Q2 2023 and bottomed at -$53.3 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $276750.0, with a median of $2.0 million recorded in 2025.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 99.93% in 2024, then tumbled 11211.11% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at -$53.3 million in 2023, then surged by 100.03% to $18000.0 in 2024, then surged by 11011.11% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $2.0 million in Q4 2025, -$2.0 million in Q2 2025, and $2.0 million in Q1 2025.